Login / Signup

Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.

Tzong-Yow WuPao-Yu ChenJann-Tay WangWang-Da LiuYee-Chun ChenShan-Chwen Chang
Published in: The Journal of antimicrobial chemotherapy (2024)
Keyphrases
  • combination therapy
  • sars cov
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • respiratory syndrome coronavirus
  • respiratory failure